SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (455)2/3/2009 9:19:34 AM
From: ghmm  Read Replies (1) of 508
 
I didn't quite catch it but there were big difference in non US vs US sites of the two trial (something like 80% US in one and 60% in the other).

I am disappointed with the data personally. I think it has a descent chance at approval though (just a guess obviously) with some strings attached (e.g. Phase 4 of some sort or perhaps label implying limited benefit for one year or use).

The FVC number even though it hit was less magnitude then I'ld hoped for (30ish instead of 50% ish). On the positive 6MW which the FDA likes hit in the (failed) study but trended in the positive one.

I was wrong in my prior post on size in the two trials (my math was off) the slide showed high dose were equivalent in the two trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News